Pfizer has claimed their Covid-19 vaccine remained effective in children aged 12-15 four months after the second dose.
The pharmaceutical company said the new data – which involved 2,228 trial participants – will help support their applications for full approval across the world.
No serious safety-concerns were observed, with a follow-up of at least six months.
Pfizer CEO Albert Bourla said: “As the global health community works to increase the number of vaccinated people around the world, these additional data provide further confidence in our vaccine’s safety and effectiveness profile in adolescents.”
“This is especially important as we see rates of Covid-19 climbing in this age group in some regions, while vaccine uptake has slowed. We look forward to sharing these data with the FDA and other regulators.”
The vaccine was granted “emergency use authorisation” for adolescents in May by the US and the company will soon be seeking full approval.
The vaccine is currently fully approved in people aged 16 and older in the US.
IMAGE – Army Spc. Angel Laureano holds a vial of the COVID-19 vaccine, Walter Reed National Military Medical Center, Bethesda, Md., Dec. 14, 2020. (DoD photo by Lisa Ferdinando)